Company Overview and News
2018-10-04 sec.gov - 1
Investors in Hornbeck Offshore Services, Inc. (HOS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 21, 2018 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
In its second quarter earnings call, Hornbeck Offshore Services discussed an eventual recovery in the oil and gas industry in the Gulf of Mexico.
2018-08-09 sec.gov - 1
Investors in Hornbeck Offshore Services, Inc. (HOS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $2.00 Put had some of the highest implied volatility of all equity options today.
GD BSTC HOS PLUG
Hornbeck Offshore Services, Inc. (NYSE:HOS) Q2 2018 Results Earnings Conference Call August 2, 2018 10:00 AM ET
2018-05-21 sec.gov - 1
Hornbeck Offshore Services (HOS - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for HOS broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
Hornbeck Offshore (NYSE:HOS) recently reported its first-quarter results. As I wrote earlier, any sustained upside in the company's shares was dependent on positive fundamental changes in the U.S. Gulf of Mexico market. The first-quarter report was a good chance to evaluate the situation for the company. In short, it remains grim.
Hornbeck Offshore Services, Inc. (NYSE:HOS) Q1 2018 Earnings Conference Call May 3, 2018 10:00 AM ET
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HOS / Hornbeck Offshore Services, Inc. on message board site Silicon Investor.
as of ET